Litcius/Paper detail

Belumosudil, ROCK2-specific inhibitor, alleviates cardiac fibrosis by inhibiting cardiac fibroblasts activation

Quan Liu, Huayang Li, Shunjun Wang, Suiqing Huang, Yuan Yue, Adilai Maihemuti, Yi Zhang, Lin Huang, Li Luo, Kangni Feng, Zhongkai Wu

2022American Journal of Physiology-Heart and Circulatory Physiology14 citationsDOI

Abstract

Although ρ-associated kinase-2 (ROCK2) is the main isoform of ρ-associated kinases (ROCKs) in the heart and more important in cardiac hypertrophy and fibrosis than ρ-associated kinase-1 (ROCK1), there has not been any pharmacological approach to inhibit ROCK2 selectively. Our study demonstrates for the first time that belumosudil, the first ROCK2-specific inhibitor, effectively ameliorates cardiac hypertrophy, fibrosis, and dysfunction induced by TAC via inhibiting cardiac fibroblasts activation.

Topics & Concepts

Pressure overloadCardiac fibrosisFibrosisROCK2MedicineROCK1Muscle hypertrophyMyofibroblastMyocardial fibrosisInternal medicineEndocrinologyKinaseCancer researchRho-associated protein kinaseProtein kinase ABiologyCardiac hypertrophyCell biologyCardiac Fibrosis and RemodelingSignaling Pathways in DiseasePeptidase Inhibition and Analysis
Belumosudil, ROCK2-specific inhibitor, alleviates cardiac fibrosis by inhibiting cardiac fibroblasts activation | Litcius